Synkrino Biotherapeutics (YC S18) — Synkrino's AI, SATIS is a powerful, unbiased discovery system for…
Before you sell to, join or invest in Synkrino Biotherapeutics
MentionFox check on Synkrino Biotherapeutics: only 1 source on file so far (checked 4 November 2026). Run a full check before you rely on it. mentionfox.com/c/funding/yc-synkrino-biotherapeutics
Based on the record MentionFox holds for this company. No flag is not a clearance.
Synkrino Biotherapeutics appears in Y Combinator's company directory in the Summer 2018 batch, listed 2018-05-16. Synkrino's AI, SATIS is a powerful, unbiased discovery system for….
Synkrino Biotherapeutics is a Y Combinator company in the Summer 2018 batch. Its directory entry describes it as: Synkrino's AI, SATIS is a powerful, unbiased discovery system for…. The founders listed are Jason Barbour (Founder/CEO), David Ott (Founder/CTO) (Y Combinator directory entry, May 16, 2018).
Get an email when Synkrino Biotherapeutics changes status, grows its team or files a funding notice. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
What do you want to do with Synkrino Biotherapeutics?
Get the full cited report on Synkrino Biotherapeutics
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
Founders, titles and bios as the company published them. Photographs are our own copies of the ones on that record, so they do not break when the original link expires.
One of 60 companies held here in Healthcare › Drug Discovery and Delivery.
No investor is drawn from a Form D — the form states how many invested and never who. The one investor on this graph is named because a batch has exactly one.
Want the whole picture on Synkrino Biotherapeutics?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Synkrino Biotherapeutics: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Synkrino Biotherapeutics covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
You get an alert in MentionFox the next time this company shows up.
Is this you?
If you're behind Synkrino Biotherapeutics: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. GetFoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.
Synkrino Biotherapeutics (YC S18) — Synkrino's AI, SATIS is a powerful, unbiased discovery system for…. MentionFox, 2026-11-04. https://mentionfox.com/funding/yc-synkrino-biotherapeutics
